NDA 210166 · Takeda Pharms USA
Motegrity
Prucalopride Succinate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Dec 14, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
65
22 Phase 3, 3 recruiting
FAERS reports
2,370
1,072 serious, 57 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 17, 2025.
MOTEGRITY ® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. MOTEGRITY is a serotonin-4 (5-HT 4 ) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. ( 1 )
Mechanism: Prucalopride, a selective serotonin type 4 (5-HT 4 ) receptor agonist, is a gastrointestinal (GI) prokinetic agent that stimulates colonic peristalsis (high-amplitude propagating contractions [HAPCs]), which increases bowel motility. Prucalopride was devoid of effects mediated via 5-HT 2A , 5-HT 2B , 5-HT 3 , motilin or CCK-A receptors in vitro at concentrations exceeding 5-HT 4 receptor affinity by 150-fold or greater. In isolated GI tissues from various animal species, prucalopride facilitated acetylcholine release to enhance the amplitude of contractions and stimulate peristalsis. In rats...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 10, 2025 Supplement 4 · Efficacy LetterLabel
- Dec 14, 2018 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
- MOTEGRITY · PRUCALOPRIDE SUCCINATE EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB
- MOTEGRITY · PRUCALOPRIDE SUCCINATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Prucalopride" as an intervention, any sponsor and status, largest first.
- Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic ConstipationPivotal-lookingCompleted
MovetisIndustry
NCT00987844 · 1,775 participants · Start Jul 1998 · Primary completion Nov 2000
Drug: Prucalopride · For: Chronic Constipation
Sites: Rochester, Minnesota
- Efficacy and Safety Study of the Effect of Dose-Titration of Prucalopride for The Treatment of Chronic ConstipationPivotal-lookingCompleted
MovetisIndustry
NCT00577018 · 755 participants · Start Aug 1998 · Primary completion Sep 1999
Drug: Prucalopride; Prucalopride · For: Constipation
- Efficacy and Safety Study of Prucalopride to Treat Chronic ConstipationPivotal-lookingCompleted
MovetisIndustry
NCT00488137 · 716 participants · Start Mar 1998 · Primary completion Jul 1999
Drug: Prucalopride; Prucalopride · For: Constipation
- Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic ConstipationPivotal-lookingCompleted
MovetisIndustry
NCT01070615 · 693 participants · Start Jun 1998 · Primary completion Nov 2000
Drug: Prucalopride · For: Chronic Constipation
Sites: Edegem, Belgium
- Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic ConstipationPivotal-lookingCompleted
MovetisIndustry
NCT00485940 · 641 participants · Start Mar 1998 · Primary completion May 1999
Drug: Prucalopride; Prucalopride · For: Constipation
- Efficacy and Safety Study of Prucalopride for the Treatment of Chronic ConstipationPivotal-lookingCompleted
MovetisIndustry
NCT00483886 · 620 participants · Start Apr 1998 · Primary completion May 1999
Drug: Prucalopride; Prucalopride · For: Constipation
- Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for ColonoscopyPivotal-lookingStatus unknown
Shandong UniversityAcademic, hospital or other
NCT02781493 · 600 participants (planned) · Start Jun 2016 · Primary completion Mar 2017
Drug: 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen; 2 mg Placebo plus 2 L Polyethylene Glycol regimen · For: Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopyp
Sites: Jinan, China
- Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Randomized Controlled TrialPivotal-lookingCompleted
Guang'anmen Hospital of China Academy of Chinese Medical SciencesAcademic, hospital or other
NCT02047045 · 560 participants · Start Apr 2014 · Primary completion Aug 2016
Drug: Prucalopride · For: Constipation
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective275
- headache248
- nausea201
- diarrhoea185
- no adverse event175
- off label use174
- fatigue144
- constipation143
- inability to afford medication136
- dizziness127
- product use issue116
- insurance issue109
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 7 |
| 2015 | 18 |
| 2016 | 12 |
| 2017 | 21 |
| 2018 | 22 |
| 2019 | 228 |
| 2020 | 279 |
| 2021 | 347 |
| 2022 | 284 |
| 2023 | 288 |
| 2024 | 317 |
| 2025 | 297 |
| 2026 | 241 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Motegrity (Prucalopride Succinate)
2024 spending
$70.7M
Beneficiaries
21,866
91,612 claims
Per beneficiary
$3,232
$17.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $22,558,033 |
| 2021 | $33,358,371 |
| 2022 | $48,695,095 |
| 2023 | $61,916,752 |
| 2024 | $70,660,851 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prucalopride.
Frampton JE · Drugs 2009 · Multicenter Study, Randomized Controlled Trial
- Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis.
Ingrosso MR, Camilleri M, Tack J, et al. · Gastroenterology 2023 · Systematic Review, Research Support, N.I.H., Extramural
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Luthra P, Camilleri M, Burr NE, et al. · Lancet Gastroenterol Hepatol 2019 · Research Support, N.I.H., Extramural, Systematic Review
- Constipation in adults.
Mueller-Lissner SA, Wald A · BMJ Clin Evid 2010 · Systematic Review
- Prucalopride: For functional constipation only?
Bellini M, Gambaccini D, Bassotti G · Tech Coloproctol 2016 · Systematic Review
- Treatments for intractable constipation in childhood.
Gordon M, Grafton-Clarke C, Rajindrajith S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.